Demographics and disease characteristics at baseline of patients with available samples for biomarker analyses
| FIL (n=60) | PBO (n=61) | |
| Mean (SD) age in years | 50 (12.4) | 50 (11.1) |
| Female | 32 (53%) | 29 (48%) |
| Mean (SD) weight, kg | 80.50 (18.3) | 86.95 (17.8) |
| Mean (SD) BMI kg/m2 | 28.6 (6.6) | 30.1 (5.9) |
| Mean (SD) duration of psoriatic arthritis in years | 7 (6.9) | 7 (6.3) |
| Mean (SD) tender joint count 68 | 17.50 (8.4) | 21.81 (13.4) |
| Mean (SD) swollen joint count 66 | 11.47 (5.0) | 12.88 (6.8) |
| Mean (SD) HAQ-DI version 01 | 1.44 (0.5) | 1.41 (0.6) |
| Mean (SD) hsCRP (mg/L) | 14.5 (20.4) | 11.3 (17.8) |
| Baseline CRP≥ULN | 24 (40%) | 16 (26%) |
| Baseline psoriasis ≥3% BSA | 38 (63%) | 36 (59%) |
| Median PASI (IQR) | 6.5 (2.6–15.0) | 6.9 (3.8–16.3) |
| Mean (SD) PASDAS | 6.03 (0.8) | 6.18 (1.0) |
| Mean (SD) DAPSA | 42.93 (13.2) | 48.33 (20.2) |
| No of patients with enthesitis based on SPARCC Enthesitis Index | 33 (55%) | 45 (74%) |
| Mean (SD) SPARCC Enthesitis Index Score | 4.70 (2.9) | 5.80 (3.7) |
| No of patients with enthesitis based on LEI | 29 (48%) | 41 (67%) |
| Mean (SD) LEI | 2.66 (1.3) | 2.63 (1.4) |
| No of patients with prior anti-TNF therapy | 11 (18%) | 8 (13%) |
| No of patients with concurrent use of csDMARD | 46 (77%) | 45 (74%) |
| No of patients with concurrent use of steroids | 16 (27%) | 16 (26%) |
BMI, body mass index; BSA, body surface area; csDMARD, conventional synthetic disease modifying antirheumatic drugs; DAPSA, Disease Activity Index for Psoriatic Arthritis; HAQ-DI, Health Assessment Questionnaire Disability Index; hsCRP, high sensitivity C reactive protein; LEI, Leeds Enthesitis Index; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI, Psoriasis Area and Severity Index; SPARCC, Spondyloarthritis Research Consortium of Canada; TNF, tumour necrosis factor; ULN, upper limit of normal.